相关实验视频

Updated: Apr 17, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

突变性肺腺癌细胞衍生异位体miR-651-5p 通过降低BCL2表达的调节诱导CD8+T细胞亡

Chao Zhao¹, Lei Cheng¹, Aiwu Li²

¹Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.

|February 26, 2025

概括

EGFR突变肺癌通过通过外体miR-651-5p促进T细胞死亡来阻碍免疫治疗. 抑制miR-651-5p可以增加T细胞透和PD-1疗法的有效性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

编程细胞死亡1 (PD-1) 抑制剂在表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 中表现出有限的疗效.
CD8+瘤透淋巴细胞 (TILs) 对于免疫治疗反应至关重要,但在EGFR突变NSCLC中被减少.
了解EGFR突变NSCLC减少TIL背后的机制对于改善治疗结果至关重要.

研究的目的:

研究微RNA (miRNA) 在EGFR突变肺腺癌中调解免疫逃避中的作用.
阐明EGFR突变影响T细胞透和亡的机制.
探索向外体miR-651-5p的潜力,作为一种治疗策略,以增强EGFR突变NSCLC的免疫治疗.

主要方法:

使用数据库分析,临床标本,小RNA测序和单细胞测序分析miRNA表达和免疫细胞透的分析.
试验室研究涉及细胞共同培养和流细胞计,以评估免疫细胞亡.
使用人性化的小鼠模型进行体内研究,以评估miR-651-5p抗体与PD-1抑制剂结合的治疗效果.

主要成果:

外体miR-651-5p在EGFR突变肺腺癌和诱导CD8+T细胞亡中显著上调.
通过FOS激活EGFR信号通路,促进了miR-651-5p的表达,该表达准BCL2以增强T细胞亡.
在临床前模型中,服用miR-651-5p对抗体增加了T细胞透,并改善了PD-1抑制剂的抗瘤疗效.

结论:

EGFR突变肺腺癌通过增加外体miR-651-5p来抑制抗瘤免疫力,从而导致T细胞亡.
用抗体向外体miR-651-5p是一种有前途的策略,可以增强免疫细胞透.
与miR-651-5p抗剂和PD-1抑制剂的联合治疗可以克服EGFR突变NSCLC患者的免疫疗法耐药性.

关键词:

灭症 (apoptosis) 是一种死亡的过程.皮肤上生长因子受体.外基因组是外基因组的组成部分.非小细胞肺癌的肺癌.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

The Extrinsic Apoptotic Pathway

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...